CA2352439A1 - Fabrication de virus oncolytiques - Google Patents

Fabrication de virus oncolytiques Download PDF

Info

Publication number
CA2352439A1
CA2352439A1 CA 2352439 CA2352439A CA2352439A1 CA 2352439 A1 CA2352439 A1 CA 2352439A1 CA 2352439 CA2352439 CA 2352439 CA 2352439 A CA2352439 A CA 2352439A CA 2352439 A1 CA2352439 A1 CA 2352439A1
Authority
CA
Canada
Prior art keywords
cells
pkr
viral
virus
hsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2352439
Other languages
English (en)
Inventor
Patrick W. K. Lee
Faris Farassati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA 2352439 priority Critical patent/CA2352439A1/fr
Priority to AU2002354841A priority patent/AU2002354841A1/en
Priority to PCT/CA2002/001108 priority patent/WO2003008586A2/fr
Publication of CA2352439A1 publication Critical patent/CA2352439A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA 2352439 2001-07-17 2001-07-17 Fabrication de virus oncolytiques Abandoned CA2352439A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA 2352439 CA2352439A1 (fr) 2001-07-17 2001-07-17 Fabrication de virus oncolytiques
AU2002354841A AU2002354841A1 (en) 2001-07-17 2002-07-17 Engineering oncolytic viruses
PCT/CA2002/001108 WO2003008586A2 (fr) 2001-07-17 2002-07-17 Ingenieurie de virus oncolytiques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2352439 CA2352439A1 (fr) 2001-07-17 2001-07-17 Fabrication de virus oncolytiques

Publications (1)

Publication Number Publication Date
CA2352439A1 true CA2352439A1 (fr) 2003-01-17

Family

ID=4169411

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2352439 Abandoned CA2352439A1 (fr) 2001-07-17 2001-07-17 Fabrication de virus oncolytiques

Country Status (3)

Country Link
AU (1) AU2002354841A1 (fr)
CA (1) CA2352439A1 (fr)
WO (1) WO2003008586A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20100221228A1 (en) * 2006-01-24 2010-09-02 The University Of Chicago y134.5 Deficient HSV and the MAPK Pathway
EP2349296B1 (fr) 2008-08-21 2017-04-05 Ottawa Hospital Research Institute Symbiose virale oncolytique synergique obtenue par génie génétique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118942A (en) * 1995-07-27 2002-09-12 American Cyanamid Co Nonviolent viruses used as killers - tumors and vaccines
JPH1087503A (ja) * 1996-09-06 1998-04-07 Nippon Chem Res Kk 神経系腫瘍細胞のアポトーシス剤
HUP0302278A3 (en) * 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses

Also Published As

Publication number Publication date
AU2002354841A1 (en) 2003-03-03
WO2003008586A2 (fr) 2003-01-30
WO2003008586A3 (fr) 2003-10-16

Similar Documents

Publication Publication Date Title
Cassady et al. The herpes simplex virus US11 protein effectively compensates for the γ134. 5 gene if present before activation of protein kinase R by precluding its phosphorylation and that of the α subunit of eukaryotic translation initiation factor 2
Cheng et al. Herpes simplex virus 1 infection activates the endoplasmic reticulum resident kinase PERK and mediates eIF-2α dephosphorylation by the γ134. 5 protein
Prichard et al. Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes
Mohr et al. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function.
Muganda et al. Human cytomegalovirus elevates levels of the cellular protein p53 in infected fibroblasts
Schang et al. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription
Yao et al. Association of ICP0 but not ICP27 with purified virions of herpes simplex virus type 1
Grimm et al. Analysis of viral and cellular factors influencing herpesvirus-induced nuclear envelope breakdown
Marschall et al. Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97
Aurelian et al. Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10)
Davido et al. The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters the posttranslational modification of herpes simplex virus type 1 ICP0
Atkin et al. Polyoma virus and simian virus 40 as cancer models: history and perspectives
Mostafa et al. N-terminal phosphorylation sites of herpes simplex virus 1 ICP0 differentially regulate its activities and enhance viral replication
Mittnacht et al. Viral cyclins
Jia et al. Murine gammaherpesvirus 68 open reading frame 45 plays an essential role during the immediate-early phase of viral replication
Cheng et al. Dephosphorylation of eIF-2α mediated by the γ134. 5 protein of herpes simplex virus type 1 is required for viral response to interferon but is not sufficient for efficient viral replication
Kadeppagari et al. HSV-2 inhibits type-I interferon signaling via multiple complementary and compensatory STAT2-associated mechanisms
Albright et al. The herpes simplex virus UL37 protein is phosphorylated in infected cells
Lin et al. Epstein-Barr virus nuclear antigen 2 retards cell growth, induces p21WAF1 expression, and modulates p53 activity post-translationally
Strand et al. Role of the VP16-binding domain of vhs in viral growth, host shutoff activity, and pathogenesis
Wolf et al. Characterization of the human cytomegalovirus UL97 gene product as a virion-associated protein kinase
CA2352439A1 (fr) Fabrication de virus oncolytiques
Isler et al. Phosphorylation of the herpes simplex virus type 1 origin binding protein
Gregory et al. Characterization of mre11 loss following HSV-1 infection
Vázquez et al. A short sequence immediately upstream of the internal repeat elements is critical for KSHV LANA mediated DNA replication and impacts episome persistence

Legal Events

Date Code Title Description
FZDE Dead